Anixa Biosciences, Inc. (NASDAQ: ANIX) has completed the final patient visit in its Phase 1 clinical trial evaluating a novel breast cancer vaccine, which was invented at Cleveland Clinic. The trial enrolled a total of 35 women across three cohorts: 26 patients with triple-negative breast cancer at risk of recurrence, four women in a prevention group with genetic mutations who opted for preventive mastectomy, and five patients who received the vaccine in combination with pembrolizumab. According to company statements, full clinical results will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025, following the submission of final study reports to the U.S. Department of Defense and the FDA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN93285) on October 08, 2025, and is solely responsible for the information contained therein.